ArticleGynecologic oncology reports2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synthetic lethality in cancer: mechanism exploration and therapeutic applications.Cell communication and signaling : CCS · 2026Review
- Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO).International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Purpose: Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS. Patients and methods: This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed Results: 9 patients enrolled prior to drug discontinuation by the sponsor. ORR was 22.2 % (95 % CI 2.8-60 %) with 2 partial responses. 3 patients (33.3 %) had stable disease. Median PFS was 2.7 months (95 % CI 0.9 - not reached). Treatment-related adverse events (all grades) occurred in 8 patients (88.9 %), most commonly diarrhea (77.8 %) and fatigue (66.7 %). Conclusion: In this phase II trial of 9 patients with
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.